All Updates

All Updates

icon
Filter
Partnerships
Catapult Health partners with Tasso to enhance preventive healthcare services
Preventive Healthcare
Sep 30, 2022
This week:
Funding
Matr Foods raises EUR 20 million in debt funding to build mycelium meat factory
Plant-based Meat
Today
Last week:
M&A
Platform Science to acquire Trimble's global transportation telematics business units
Truck Industry Tech
Yesterday
Funding
Whatfix raises USD 100 million in Series E funding to expand business
EdTech: Corporate Learning
Yesterday
Product updates
Sky Mavis launches cross-game onboarding solution
Web3 Ecosystem
Sep 14, 2024
Funding
Bicara Therapeutics raises USD 315 million in IPO; plans to develop lead candidate ficerafusp alfa
Precision Medicine
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Precision Medicine
Sep 13, 2024
Partnerships
Moffitt Cancer Center partners with AstraZeneca to advance oncology cell therapies
Cell & Gene Therapy
Sep 13, 2024
Product updates
Quandela launches European quantum computer in North America
Quantum Computing
Sep 13, 2024
Partnerships
IonQ achieves high qubit gate fidelity on barium development platform
Quantum Computing
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Clinical Trial Technology
Sep 13, 2024
Preventive Healthcare

Preventive Healthcare

Sep 30, 2022

Catapult Health partners with Tasso to enhance preventive healthcare services

Partnerships

  • Preventive care provider Catapult Health partnered with medical device startup Tasso to enhance its at-home preventive care service available to Fortune 500 employers and leading health plans. 

  • The new service will be in effect from the 5th of October 2022 and will be part of Catapult’s VirtualCheckup solution. The home kit will include the FDA-approved Tasso+ device, a blood pressure monitor, and a measuring tape. A certified Catapult nurse practitioner will meet the user via a video call to discuss the biomarkers sent for their analysis and also review medication, family history, and depression, and create a personalized action plan.

  • Early September 2022, Tasso received its FDA approval for the Tasso+ device which will be marketed to pharmaceuticals, healthcare providers, and academic institutions in the US. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.